The administration wants drugmakers to bring medication prices more closely in line with the Most-Favored Nation pricing approach.

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

Elsewhere, the U.S. trade deficit narrowed in June by more than anticipated in June, reflecting a dip in imports at the end ...

Pfizer raised its full-year profit forecast on Tuesday while reporting second-quarter results that topped Wall Street ...

Pfizer beat earnings expectations and improved its outlook for the rest of the year, despite fresh statements from Trump ...

US market rise on Palantir’s strong earnings while Trump’s tariff threats and mixed corporate results weigh on broader market ...

Live Updates Live Coverage Updates appear automatically as they are published. Investors Don't Like the Taste of Yum! 9:37 am ...

Pfizer (PFE) increased its 2025 profit outlook by 10 cents a share to a range of $2.90 to $3.10 a share, citing continued cost cuts, a lower tax rate and "confidence" that strength seen in the first ...

Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 ...

Pfizer stock rose after the drugmaker posted adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer raised its full-year profit forecast on Tuesday while reporting second-quarter results that topped Wall Street ...